Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Infinity Pharmaceuticals Inc (INFIQ)

OTC Markets
Currency in USD
Disclaimer
0.018
0.000(0.00%)
Closed
INFIQ Scorecard
Full Analysis
Stock generally trades with high price volatility
Trading near 52-week High
Fair Value
Day's Range
0.0180.018
52 wk Range
0.0010.018
Prev. Close
-
Open
0.018
Day's Range
0.018-0.018
52 wk Range
0.001-0.018
Volume
0
Average Vol. (3m)
182,849
1-Year Change
350%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
INFIQ Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Infinity Pharmaceuticals Inc Company Profile

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.

Compare INFIQ to Peers and Sector

Metrics to compare
INFIQ
Peers
Sector
Relationship
P/E Ratio
0.0x−3.6x−0.6x
PEG Ratio
0.000.180.00
Price / Book
0.0x2.0x2.6x
Price / LTM Sales
0.0x18.3x3.2x
Upside (Analyst Target)
0.0%32.2%44.2%
Fair Value Upside
Unlock0.8%7.9%Unlock

FAQ

What Is the Infinity (INFIQ) Stock Price Today?

The Infinity stock price today is 0.018

What Stock Exchange Does Infinity Trade On?

Infinity is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Infinity?

The stock symbol for Infinity is "INFIQ."

What Is the Infinity Market Cap?

As of today, Infinity market cap is 90.00null.

What is Infinity Earnings Per Share?

The Infinity EPS is -0.458.

What Is the Next Infinity Earnings Date?

Infinity will release its next earnings report on Nov 11, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.